How Much Does Vyleesi (Bremelanotide) Cost in Vermont in 2026?

Vermont Retail Pricing for Vyleesi in 2026

Brand-name Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) costs approximately $1,200 per month at Vermont retail pharmacies when purchased without insurance. That figure mirrors the manufacturer list price set by Palatin Technologies and has held steady through early 2026.

Why the Price Stays High

Vyleesi has no FDA-approved generic equivalent. Bremelanotide remains protected by composition-of-matter patents, and no abbreviated new drug application (ANDA) has been filed with the FDA as of May 2026. Without generic competition, pharmacies lack use to negotiate lower acquisition costs from the distributor. The FDA-approved prescribing information limits Vyleesi to on-demand use (no more than 8 doses in a 30-day window), so monthly unit volume per patient stays low compared to daily-use medications.

Pharmacy-to-Pharmacy Variation

Price differences across Vermont pharmacies are minimal for brand Vyleesi because wholesale acquisition cost is uniform. Independent pharmacies in Burlington or Montpelier may offer $10 to $30 off through their own discount programs, but the baseline rarely drops below $1,150 without insurance or a manufacturer coupon. Checking both chain and independent pharmacies before filling is still worth the call.

Vermont Medicaid Coverage for Bremelanotide

Vermont Medicaid does cover Vyleesi, though the program requires prior authorization (PA) before dispensing. The PA process confirms that the patient meets clinical criteria for HSDD as defined by the DSM-5 diagnostic framework and that other potential causes of low desire (medication side effects, relationship distress, hormonal imbalance) have been evaluated.

What the PA Requires

A prescriber must submit documentation showing that the patient is a premenopausal woman with acquired, generalized HSDD causing marked distress. Vermont Medicaid typically asks for evidence that the condition is not explained by a co-existing psychiatric disorder, substance use, or another medical condition. Approval periods vary, but most initial authorizations span 6 to 12 months with renewal options.

Processing Timeline

PA decisions in the Vermont Medicaid system usually take 3 to 5 business days for standard requests. Urgent requests can receive a decision within 24 hours. If denied, patients have the right to appeal through the Department of Vermont Health Access (DVHA) fair-hearing process.

Private Insurance Coverage in Vermont

Coverage varies by plan, but several major insurers operating in Vermont include Vyleesi on their formularies, usually at a specialty or non-preferred brand tier.

Blue Cross Blue Shield of Vermont

BCBSVT plans often place Vyleesi on Tier 3 or Tier 4, resulting in copays between $75 and $250 per fill depending on the specific plan. PA is almost always required. Members should verify formulary placement through their plan documents or call the number on the back of their insurance card.

MVP Health Care

MVP, one of the larger commercial carriers in Vermont, may cover bremelanotide under its specialty pharmacy benefit. Copays and coinsurance rates depend on the employer group or individual plan selected. PA is standard.

Cigna and UnitedHealthcare

Both carriers have a presence in the Vermont marketplace. Coverage policies for Vyleesi generally require PA demonstrating HSDD diagnosis, failure or contraindication of other therapies, and confirmation that the patient is premenopausal. Coinsurance for specialty drugs on these plans often runs 20% to 33% of the allowed amount, which can still leave a patient paying $240 to $400 per month before any copay cap or out-of-pocket maximum kicks in.

How to Check Your Plan

Call your insurer's pharmacy benefits line and ask three specific questions: (1) Is bremelanotide on formulary? (2) What tier? (3) What PA criteria apply? Having answers in writing before your prescriber submits the PA saves time and prevents surprise denials.

Compounded Bremelanotide in Vermont

Compounded bremelanotide is available in Vermont through licensed 503A compounding pharmacies and offers a dramatic cost reduction compared to brand Vyleesi.

Legality and Regulatory Status

Vermont permits 503A compounding pharmacies to prepare bremelanotide formulations with a valid patient-specific prescription. Under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act), a 503A pharmacy compounds medications based on individual prescriptions from licensed prescribers. The compound must use USP-grade active pharmaceutical ingredients. Vermont's Board of Pharmacy oversees compliance at the state level.

Cost Comparison

Compounded bremelanotide costs approximately $140 per month through a licensed 503A pharmacy, compared to $1,200 for the brand autoinjector. That is an 88% reduction. The compounded version is typically supplied as a multi-dose vial with syringes rather than the pre-filled autoinjector device.

Trade-offs to Consider

The compounded product does not carry FDA approval and is not subject to the same bioequivalence testing as the branded autoinjector. Injection technique matters: patients using a vial-and-syringe setup need proper training from their pharmacist or prescriber. The RECONNECT trial (N=1,247) that supported Vyleesi's FDA approval used the branded autoinjector, so the clinical evidence base applies directly to that formulation. Compounded versions use the same active molecule, but delivery device, excipients, and sterility assurance differ.

Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer savings card that can reduce the out-of-pocket cost for commercially insured patients filling brand Vyleesi.

Eligibility

The savings card is available to patients with commercial (private) insurance. Patients covered by Medicare, Medicaid, TRICARE, or other federal or state government programs are not eligible. Vermont residents with employer-sponsored or marketplace plans typically qualify.

How It Works

Eligible patients may pay as little as $50 per fill, with the savings card covering the difference between the copay and a set ceiling (often up to $400 per fill). The card resets annually and has a maximum annual benefit. Patients can enroll through the manufacturer's website or receive a card from their prescriber's office.

Limitations

The savings card does not apply to the full cash price. It bridges the gap between insurance copay and a lower target copay. Uninsured patients paying the full $1,200 typically will not see the price drop to $50 through this program alone. For uninsured patients, the compounded route or patient assistance programs are more practical.

Telehealth Access to Vyleesi in Vermont

Vermont permits telehealth prescribing of Vyleesi. A prescriber licensed in Vermont can evaluate, diagnose, and prescribe bremelanotide through a video or audio visit without requiring an in-person exam first.

How Telehealth Visits Work for HSDD

During the visit, the clinician takes a sexual health history, screens for exclusionary conditions (uncontrolled hypertension is a contraindication, as bremelanotide can transiently raise blood pressure by 6 to 12 mmHg per the FDA label), and discusses dosing logistics. If appropriate, the prescription is sent electronically to the patient's preferred pharmacy.

Benefits for Rural Vermont Patients

Vermont's population density is low. Residents in the Northeast Kingdom, the Upper Valley, or the Champlain Islands may live 60+ miles from a sexual medicine specialist. Telehealth removes that barrier entirely. Several national telehealth platforms and Vermont-based practices offer HSDD consultations with prescribers experienced in bremelanotide.

Clinical Evidence Behind the Price Tag

Vyleesi's efficacy data come primarily from the RECONNECT phase III program, two randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD.

RECONNECT Trial Results

At 24 weeks, bremelanotide-treated patients showed a statistically significant increase in satisfying sexual events (SSEs) and a decrease in distress related to low sexual desire compared to placebo (Kingsberg et al., Obstet Gynecol 2019). The mean increase in SSEs was modest: approximately 0.5 additional events per month above placebo. Desire scores on the Female Sexual Function Index (FSFI) improved by 0.4 to 0.6 points more than placebo.

What Clinicians Say

Dr. Sheryl Kingsberg, lead investigator of the RECONNECT program, noted that "the on-demand mechanism allows women to use the medication only when they choose, unlike daily oral therapies." That flexibility is part of why some patients prefer bremelanotide over flibanserin (Addyi), which requires nightly dosing.

Safety Considerations

The most common side effect was nausea (40% of patients in trials vs. 1% placebo), which typically diminished after the first few doses. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease because of its transient pressor effect. The Endocrine Society's clinical practice guidelines recommend cardiovascular screening before initiation.

Strategies to Lower Your Vyleesi Cost in Vermont

Reducing out-of-pocket spending on bremelanotide in Vermont comes down to five concrete options.

1. Use Insurance PA Early

If you have commercial insurance or Vermont Medicaid, start the prior authorization process before your first fill. Delays cost money if you pay cash while waiting.

2. Apply the Manufacturer Savings Card

Commercially insured patients should activate the Palatin savings card before picking up their prescription. Stacking the card on top of insurance can bring copays below $75.

3. Consider Compounded Bremelanotide

At $140 per month through a licensed 503A pharmacy, compounded bremelanotide is the lowest-cost option. Ask your prescriber whether this route is appropriate for you. Confirm the pharmacy holds a valid Vermont compounding license.

4. Compare Pharmacy Prices

GoodRx, RxSaver, and similar aggregators may show price variation among Vermont pharmacies for brand Vyleesi. While the spread is narrow (usually $1,150 to $1,250), every dollar counts on a specialty medication.

5. Ask About Dose Optimization

Because bremelanotide is used on-demand (not daily), patients who use fewer than 8 doses per month may find their effective monthly cost lower than the list price. A patient using 4 doses per month is spending roughly $600 if purchasing by the dose rather than a full monthly supply.

Vermont-Specific Regulatory Notes

Vermont has adopted telehealth-friendly prescribing laws that do not require an initial in-person visit for controlled or non-controlled prescription drugs. Bremelanotide is not a controlled substance, which simplifies the prescribing pathway.

Compounding Pharmacy Oversight

The Vermont Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. Out-of-state 503A pharmacies shipping into Vermont must hold a non-resident pharmacy license. Before ordering compounded bremelanotide from an out-of-state pharmacy, patients should verify the pharmacy's Vermont non-resident license status through the Board's online lookup.

No State-Level Price Cap

Vermont does not impose a price ceiling on specialty pharmaceuticals. The state's Green Mountain Care Board reviews insurance rate increases but does not set drug prices directly. Cost containment for patients therefore depends on insurance negotiation, PA pathways, and compounding alternatives rather than regulatory price controls.